Lexicon Pharmaceuticals (NASDAQ:LXRX) said that the FDA has asked for additional time to review additional data for the potential resubmission of the marketing application for Zynquista (sotagliflozin) in adults with type 1 diabetes. This submission of additional clinical data follows ...